CAS 67-30-1|Tetrac
| Common Name | Tetrac | ||
|---|---|---|---|
| CAS Number | 67-30-1 | Molecular Weight | 747.82900 |
| Density | 2.727g/cm3 | Boiling Point | 544.8ºC at 760 mmHg |
| Molecular Formula | C14H8I4O4 | Melting Point | 230 °C |
| MSDS | ChineseUSA | Flash Point | 283.3ºC |
| Symbol | GHS06 | Signal Word | Danger |
Names
| Name | 2-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]acetic acid |
|---|---|
| Synonym | More Synonyms |
Tetrac BiologicalActivity
| Description | Tetrac (Tetraiodothyroacetic acid), a deaminated analogue of L-thyroxine (T4), and is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T3 and T4 as well as different growth factors-mediated angiogenesis. Tetra also has anticancer activity[1][2]. |
|---|---|
| Related Catalog | Research Areas >>Cancer |
| In Vitro | Tetrac (0.01-1 μM; 2-6 d) induces anti-proliferation in HT-29 and HCT116 cells with different K-RAS status[3]. Tetrac (0.1 μM; 30 min) inhibits activation of ERK1/2 in HT-29 and HCT116 cells[3]. Tetrac (0.1 μM; 24 h) inhibits expression of CCND1 and c-Myc, but promotes expression of CASP2 and THBS1[3]. Cell Proliferation Assay[3] Cell Line: HT-29 and HCT116 cells Concentration: 0.01, 0.1, 1 μM Incubation Time: 0, 2, 4, 6 days Result: Induced anti-proliferation of K-RAS wild-type colorectal cancer cells. Western Blot Analysis[3] Cell Line: HT-29 and HCT116 cells Concentration: 0.1 μM Incubation Time: 30 min Result: Inhibited constitutively activated ERK1/2, and this inhibition can remove by anti-integrin αvβ3 antibody pretreatment. |
| In Vivo | Tetrac (35 μg; p.o. for 40 days) inhibits tumor inoculation, growth and integrin expression in mice[4]. Animal Model: Wild-type male Balb/C mice aged 8 weeks are inoculated with 102B16F10 or B16LS9 cells[4] Dosage: 35 μg per day Administration: P.o. (added to the drinking water) daily for 40 days Result: Delayed the onset of ocular melanoma. Reduced the S-100 and integrin staining level in the B16F10 mice model. |
| References | [1]. Schmohl KA, et, al. Tetrac as an anti-angiogenic agent in cancer. Endocr Relat Cancer. 2019 Jun 1; 26(6):R287-R304. [2]. Davis PJ, et, al. Nongenomic Actions of Thyroid Hormone: the Integrin Component. Physiol Rev. 2020 Jun 25. [3]. Chin YT, et, al. Tetrac and NDAT Induce Anti-proliferation via Integrin αvβ3 in Colorectal Cancers With Different K-RAS Status. Front Endocrinol (Lausanne). 2019 Mar 12; 10:130. [4]. Ashur-Fabian O, et, al. Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model. Front Endocrinol (Lausanne). 2019 Jan 8; 9:775. [5]. Rajabi M, et, al. Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer. Bioorg Med Chem Lett. 2018 Apr 15;28(7):1223-1227. |
Chemical & Physical Properties
| Density | 2.727g/cm3 |
|---|---|
| Boiling Point | 544.8ºC at 760 mmHg |
| Melting Point | 230 °C |
| Molecular Formula | C14H8I4O4 |
| Molecular Weight | 747.82900 |
| Flash Point | 283.3ºC |
| Exact Mass | 747.66000 |
| PSA | 66.76000 |
| LogP | 5.23000 |
| Index of Refraction | 1.801 |
| InChIKey | PPJYSSNKSXAVDB-UHFFFAOYSA-N |
| SMILES | O=C(O)Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1 |
Safety Information
| Symbol | GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H300 |
| Precautionary Statements | P264-P301 + P310 |
| Personal Protective Equipment | Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | T+ |
| Risk Phrases | 28 |
| Safety Phrases | 45 |
| RIDADR | UN 2811 6.1/PG 1 |
| RTECS | CY1585800 |
| Hazard Class | 6.1 |
| HS Code | 2918990090 |
Customs
| HS Code | 2918990090 |
|---|---|
| Summary | 2918990090. other carboxylic acids with additional oxygen function and their anhydrides, halides, peroxides and peroxyacids; their halogenated, sulphonated, nitrated or nitrosated derivatives. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Articles28
More Articles| Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor J. Control. Release 164(2) , 213-20, (2012) Nanoparticles have demonstrated potential for promoting drug delivery to tumor sites and enhancing uptake. Here, we report tetraiodothyroacetic acid (tetrac) as a promising new targeting moiety for de... | |
| Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid 20(3) , 281-6, (2010) Tetraiodothyroacetic acid (tetrac) is a deaminated analogue of L-thyroxine that blocks the actions of L-thyroxine and 3,5,3'-triiodo-L-thyronine at the cell surface receptor for thyroid hormone on int... | |
| Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts. Lung Cancer 76(1) , 39-45, (2012) Thyroid hormone stimulates cell proliferation of several types of cancers and stimulates cancer-relevant angiogenesis. In the present study, we investigated the proliferative effect of thyroid hormone... |
Synonyms
| 5-diiodophenoxy)-3 |
| Thyroacetic acid,3,3',5,5'-tetraiodo |
| 3,5-Diiodo-4-(4-hydroxy-3,5-diiodophenoxy)benzeneacetic acid |
| Tetrac |
| MFCD00055932 |
| [4-(4-hydroxy-3 |
| 4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenylacetic acid |
| Benzeneacetic acid,3,5-diiodo-4-(4-hydroxy-3,5-diiodophenoxy) |
| 3,3',5,5'-TETRAIODOTHYROACETIC ACID |
| Tetraiodothyroacetic acid |
| Acide 3,5,3',5'-tetraiodothyroacetique [French] |
| 5-diiodophenyl] acetic acid |
| EINECS 200-649-1 |
